| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Leukemias |
aVaccine & Infectious Disease Institute (VIDI), Laboratory of Experimental Hematology, Faculty of Medicine, University of Antwerp, Antwerp, Belgium; bCenter for Cellular Therapy and Regenerative Medicine, Antwerp University Hospital, Antwerp, Belgium
Key Words. Myeloid leukemia • Active immunotherapy • Passive immunotherapy
Correspondence: Viggo F.I. Van Tendeloo, VIDI, Laboratory of Experimental Hematology, University of Antwerp (UA), Antwerp University Hospital (UZA), Wilrijkstraat 10, B-2650 Antwerp, Belgium. Telephone: 32-3-8213661; Fax: 32-3-8214456; e-mail: viggo.van.tendeloo{at}uza.be
Received August 1, 2008; accepted for publication February 16, 2009; first published online in THE ONCOLOGIST Express on March 16, 2009.
Disclosures
Evelien L.J.M. Smits: None; Zwi N. Berneman: None; Viggo F.I. Van Tendeloo: None.
Section editors Bob Löwenberg and Joseph G. Jurcic have disclosed no financial relationships relevant to the content of this article.
The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias.
Target audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in leukemias.
Following standard therapy that consists of chemotherapy with or without stem cell transplantation, both relapsed and refractory disease shorten the survival of acute myeloid leukemia (AML) patients. Therefore, additional treatment options are urgently needed, especially to fight residual AML cells. The identification of leukemia-associated antigens and the observation that administration of allogeneic T cells can mediate a graft-versus-leukemia effect paved the way to the development of active and passive immunotherapy strategies, respectively. The aim of these strategies is the eradication of AML cells by the immune system. In this review, an overview is provided of both active and passive immunotherapy strategies that are under investigation or in use for the treatment of AML. For each strategy, a critical view on the state of the art is given and future perspectives are discussed.
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |